Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT04598269

Public ClinicalTrials.gov record NCT04598269. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 1:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2a, Multicenter, Randomized, Double-blind, Vehicle-controlled, Parallel-group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Study identification

NCT ID
NCT04598269
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Enrollment
50 participants

Conditions and interventions

Interventions

  • ATI-1777 Drug
  • Vehicle Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 29, 2020
Primary completion
Apr 7, 2021
Completion
Apr 21, 2021
Last update posted
Sep 27, 2023

2020 – 2021

United States locations

U.S. sites
14
U.S. states
11
U.S. cities
14
Facility City State ZIP Site status
Aclaris Investigational Site Scottsdale Arizona 85260
Aclaris Investigational Site Encino California 91436
Aclaris Investigational Site Los Angeles California 90045
Aclaris Investigational Site Tampa Florida 33613
Aclaris Investigational Site Indianapolis Indiana 46250
Aclaris Investigational Site Overland Park Kansas 66215
Aclaris Investigational Site Omaha Nebraska 68144
Aclaris Investigational Site Kew Gardens New York 11415
Aclaris Investigational Site Newtown Square Pennsylvania 19073
Aclaris Investigational Site Fountain Inn South Carolina 29644
Aclaris Investigational Site Austin Texas 78759
Aclaris Investigational Site San Antonio Texas 78213
Aclaris Investigational Site Lynchburg Virginia 24501
Aclaris Investigational Site Newport News Virginia 23606

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04598269, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 27, 2023 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04598269 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →